Capmatinib Hydrochloride interactions
Checked as Capmatinib in this data source.
Full monograph for Capmatinib HydrochlorideCheck it against another medicine
Medicines
190 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Apalutamide | Major | Metabolism | Coadministration with strong or moderate CYP450 3A4 inducers may decrease the plasma concentrations and anti-tumor activity of capmatinib. The proposed… | 5 sources — open the full entry |
| Bosentan Monohydrate | Major | Metabolism | Coadministration with strong or moderate CYP450 3A4 inducers may decrease the plasma concentrations and anti-tumor activity of capmatinib. The proposed… | 5 sources — open the full entry |
| Calcium Dobesilate + Lidocaine + Dexamethasone | Major | Metabolism | Coadministration with strong or moderate CYP450 3A4 inducers may decrease the plasma concentrations and anti-tumor activity of capmatinib. The proposed…2 documented mechanisms | 6 sources — open the full entry |
| Carbamazepine | Major | Metabolism | Coadministration with strong or moderate CYP450 3A4 inducers may decrease the plasma concentrations and anti-tumor activity of capmatinib. The proposed… | 5 sources — open the full entry |
| Cenobamate | Major | Metabolism | Coadministration with strong or moderate CYP450 3A4 inducers may decrease the plasma concentrations and anti-tumor activity of capmatinib. The proposed… | 5 sources — open the full entry |
| Ceritinib | Major | Metabolism | Coadministration of capmatinib with strong CYP450 3A4 inhibitors may increase the risk and severity of capmatinib adverse effects, such as interstitial lung… | 3 sources — open the full entry |
| Ciprofloxacin + Dexamethasone | Major | Metabolism | Coadministration with strong or moderate CYP450 3A4 inducers may decrease the plasma concentrations and anti-tumor activity of capmatinib. The proposed…2 documented mechanisms | 6 sources — open the full entry |
| Clarithromycin | Major | Metabolism | Coadministration of capmatinib with strong CYP450 3A4 inhibitors may increase the risk and severity of capmatinib adverse effects, such as interstitial lung… | 3 sources — open the full entry |
| Colchicine | Major | Excretion | Coadministration with inhibitors of P-glycoprotein (P-gp) may significantly increase the serum concentrations of colchicine. The mechanism involves enhanced… | 78 sources — open the full entry |
| Dexamethasone | Major | Metabolism | Coadministration with strong or moderate CYP450 3A4 inducers may decrease the plasma concentrations and anti-tumor activity of capmatinib. The proposed… | 5 sources — open the full entry |
| Dexamethasone + Chloramphenicol | Major | Metabolism | Coadministration with strong or moderate CYP450 3A4 inducers may decrease the plasma concentrations and anti-tumor activity of capmatinib. The proposed…2 documented mechanisms | 6 sources — open the full entry |
| Dexamethasone + Levofloxacin | Major | Metabolism | Coadministration with strong or moderate CYP450 3A4 inducers may decrease the plasma concentrations and anti-tumor activity of capmatinib. The proposed… | 5 sources — open the full entry |
| Dexamethasone + Neomycin + Glacial Acetic Acid | Major | Metabolism | Coadministration with strong or moderate CYP450 3A4 inducers may decrease the plasma concentrations and anti-tumor activity of capmatinib. The proposed… | 5 sources — open the full entry |
| Dexamethasone + Neomycin Sulphate + Polymyxin B Sulphate | Major | Metabolism | Coadministration with strong or moderate CYP450 3A4 inducers may decrease the plasma concentrations and anti-tumor activity of capmatinib. The proposed… | 5 sources — open the full entry |
| Dexamethasone + Tobramycin | Major | Metabolism | Coadministration with strong or moderate CYP450 3A4 inducers may decrease the plasma concentrations and anti-tumor activity of capmatinib. The proposed… | 5 sources — open the full entry |
| Efavirenz | Major | Metabolism | Coadministration with strong or moderate CYP450 3A4 inducers may decrease the plasma concentrations and anti-tumor activity of capmatinib. The proposed… | 5 sources — open the full entry |
| Enzalutamide | Major | Metabolism | Coadministration with strong or moderate CYP450 3A4 inducers may decrease the plasma concentrations and anti-tumor activity of capmatinib. The proposed… | 5 sources — open the full entry |
| Esomeprazole + Amoxicillin + Clarithromycin | Major | Metabolism · Others | Coadministration of capmatinib with strong CYP450 3A4 inhibitors may increase the risk and severity of capmatinib adverse effects, such as interstitial lung…2 documented mechanisms | 4 sources — open the full entry |
| Fosphenytoin Sodium | Major | Metabolism | Coadministration with strong or moderate CYP450 3A4 inducers may decrease the plasma concentrations and anti-tumor activity of capmatinib. The proposed… | 5 sources — open the full entry |
| Gatifloxacin + Dexamethasone | Major | Metabolism | Coadministration with strong or moderate CYP450 3A4 inducers may decrease the plasma concentrations and anti-tumor activity of capmatinib. The proposed… | 5 sources — open the full entry |
| Itraconazole | Major | Metabolism | Coadministration of capmatinib with strong CYP450 3A4 inhibitors may increase the risk and severity of capmatinib adverse effects, such as interstitial lung… | 3 sources — open the full entry |
| Ketoconazole | Major | Metabolism | Coadministration of capmatinib with strong CYP450 3A4 inhibitors may increase the risk and severity of capmatinib adverse effects, such as interstitial lung… | 3 sources — open the full entry |
| Ketoconazole + Zinc Pyrithione + Aleovera | Major | Metabolism | Coadministration of capmatinib with strong CYP450 3A4 inhibitors may increase the risk and severity of capmatinib adverse effects, such as interstitial lung… | 3 sources — open the full entry |
| Lamivudine + Zidovudine + Nevirapine | Major | Metabolism | Coadministration with strong or moderate CYP450 3A4 inducers may decrease the plasma concentrations and anti-tumor activity of capmatinib. The proposed… | 5 sources — open the full entry |
| Lansoprazole + Amoxicillin + Clarithromycin | Major | Metabolism · Others | Coadministration of capmatinib with strong CYP450 3A4 inhibitors may increase the risk and severity of capmatinib adverse effects, such as interstitial lung…2 documented mechanisms | 4 sources — open the full entry |
| Leflunomide | Major | Synergy | The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may… | 3 sources — open the full entry |
| Lopinavir + Ritonavir | Major | Metabolism | Coadministration of capmatinib with strong CYP450 3A4 inhibitors may increase the risk and severity of capmatinib adverse effects, such as interstitial lung… | 3 sources — open the full entry |
| Lorlatinib | Major | Metabolism | Coadministration with strong or moderate CYP450 3A4 inducers may decrease the plasma concentrations and anti-tumor activity of capmatinib. The proposed… | 5 sources — open the full entry |
| Mifepristone | Major | Metabolism | Coadministration of capmatinib with strong CYP450 3A4 inhibitors may increase the risk and severity of capmatinib adverse effects, such as interstitial lung… | 3 sources — open the full entry |
| Mifepristone + Misoprostol | Major | Metabolism | Coadministration of capmatinib with strong CYP450 3A4 inhibitors may increase the risk and severity of capmatinib adverse effects, such as interstitial lung… | 3 sources — open the full entry |
| Morphine Sulfate | Major | Absorption | Coadministration with P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of morphine and its risk of adverse effects, including… | 7 sources — open the full entry |
| Moxifloxacin Hydrochloride + Dexamethasone | Major | Metabolism | Coadministration with strong or moderate CYP450 3A4 inducers may decrease the plasma concentrations and anti-tumor activity of capmatinib. The proposed… | 5 sources — open the full entry |
| Nelfinavir | Major | Metabolism | Coadministration of capmatinib with strong CYP450 3A4 inhibitors may increase the risk and severity of capmatinib adverse effects, such as interstitial lung… | 3 sources — open the full entry |
| Nirmatrelvir + Ritonavir | Major | Metabolism | Coadministration of capmatinib with strong CYP450 3A4 inhibitors may increase the risk and severity of capmatinib adverse effects, such as interstitial lung… | 3 sources — open the full entry |
| Phenobarbital | Major | Metabolism | Coadministration with strong or moderate CYP450 3A4 inducers may decrease the plasma concentrations and anti-tumor activity of capmatinib. The proposed… | 5 sources — open the full entry |
| Phenytoin Sodium | Major | Metabolism | Coadministration with strong or moderate CYP450 3A4 inducers may decrease the plasma concentrations and anti-tumor activity of capmatinib. The proposed… | 5 sources — open the full entry |
| Pirfenidone | Major | Metabolism | Coadministration with moderate or potent inhibitors of CYP450 1A2 may significantly increase the plasma concentrations of pirfenidone, which is primarily (70%… | 5 sources — open the full entry |
| Posaconazole | Major | Metabolism | Coadministration of capmatinib with strong CYP450 3A4 inhibitors may increase the risk and severity of capmatinib adverse effects, such as interstitial lung… | 3 sources — open the full entry |
| Primidone | Major | Metabolism | Coadministration with strong or moderate CYP450 3A4 inducers may decrease the plasma concentrations and anti-tumor activity of capmatinib. The proposed… | 5 sources — open the full entry |
| Rabeprazole + Amoxicillin + Clarithromycin | Major | Metabolism · Others | Coadministration of capmatinib with strong CYP450 3A4 inhibitors may increase the risk and severity of capmatinib adverse effects, such as interstitial lung…2 documented mechanisms | 4 sources — open the full entry |
| Rasagiline | Major | Metabolism | Coadministration with inhibitors of CYP450 1A2 may increase the plasma concentrations of rasagiline, which is primarily metabolized by the isoenzyme. Because… | 14 sources — open the full entry |
| Relugolix | Major | Absorption | Coadministration with inhibitors of the P-glycoprotein (P-gp) efflux transporter may increase the plasma concentrations of relugolix, particularly when the… | 2 sources — open the full entry |
| Relugolix + Estradiol + Norethindrone | Major | Absorption | Coadministration with inhibitors of the P-glycoprotein (P-gp) efflux transporter may increase the plasma concentrations of relugolix, particularly when the… | 2 sources — open the full entry |
| Rifampicin | Major | Metabolism | Coadministration with strong or moderate CYP450 3A4 inducers may decrease the plasma concentrations and anti-tumor activity of capmatinib. The proposed… | 5 sources — open the full entry |
| Rifampicin + Isoniazid | Major | Metabolism | Coadministration with strong or moderate CYP450 3A4 inducers may decrease the plasma concentrations and anti-tumor activity of capmatinib. The proposed… | 5 sources — open the full entry |
| Rifampicin + Isoniazid + Pyrazinamide + Ethambutol | Major | Metabolism | Coadministration with strong or moderate CYP450 3A4 inducers may decrease the plasma concentrations and anti-tumor activity of capmatinib. The proposed… | 5 sources — open the full entry |
| Sotorasib | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of capmatinib. | 1 sources — open the full entry |
| Tizanidine Hydrochloride | Major | Metabolism | Coadministration with inhibitors of CYP450 1A2 may significantly increase the plasma concentrations and pharmacologic effects of tizanidine, which is a… | 8 sources — open the full entry |
| Tucatinib | Major | Metabolism | Coadministration of capmatinib with strong CYP450 3A4 inhibitors may increase the risk and severity of capmatinib adverse effects, such as interstitial lung… | 3 sources — open the full entry |
| Venetoclax | Major | Absorption | Coadministration with P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of venetoclax, which is a substrate of this efflux transporter. | 5 sources — open the full entry |
Conditions
Conditions in which Capmatinib Hydrochloride needs care, as documented in this source.
Kidney Diseases
ModerateNo clinically significant effects on the pharmacokinetic parameters of capmatinib were identified in patients with mild to moderate renal impairment. Therefore, no dosage adjustment is recommended in patients with mild or moderate renal impairment. Exercise care when using capmatinib in patients with severe renal impairment as it has not been studied in these patient population.
1 source
- "Product Information. Tabrecta (capmatinib)." Novartis Pharmaceuticals (2020):
Liver Diseases
ModerateCapmatinib is primarily metabolized by CYP450 3A4 and aldehyde oxidase and its use may cause hepatotoxicity. Assess liver function tests, including ALT, AST, and total bilirubin before administering capmatinib, every 2 weeks during the first 3 months of treatment, then once a month or as clinically indicated, with more frequent testing in patients who develop increased transaminases or bilirubin. Caution when using this agent in patients with liver disorder or a disorder of bilirubin metabolism. Withhold, reduce the dose, or permanently discontinue capmatinib based on severity of adverse reactions. No clinically significant effects on the pharmacokinetic parameters of capmatinib were identified in patients with mild, moderate or severe hepatic impairment.
1 source
- "Product Information. Tabrecta (capmatinib)." Novartis Pharmaceuticals (2020):
Lung Diseases
ModerateThe use of capmatinib may cause interstitial lung disease (ILD)/pneumonitis. Exercise care when using this agent in patients with disorders of the lung. It is recommended to monitor for new or worsening pulmonary symptoms indicative of ILD/pneumonitis. Immediately withhold treatment with capmatinib in patients with suspected ILD/pneumonitis and permanently discontinue if no other potential causes of ILD/pneumonitis are identified.
1 source
- "Product Information. Tabrecta (capmatinib)." Novartis Pharmaceuticals (2020):
PHOTOPAROXYSMAL RESPONSE 1
ModerateThe use of capmatinib may cause photosensitivity reactions. Exercise care when using this agent in patients predisposed to photosensitivity reactions or with a history of skin cancer. It is recommended that patients use precautionary measures against ultraviolet exposure such as use of sunscreen or protective clothing during treatment with capmatinib. Advise patients to limit direct ultraviolet exposure during treatment.
1 source
- "Product Information. Tabrecta (capmatinib)." Novartis Pharmaceuticals (2020):